Abstract
A clinical evaluation was made of the efficacy of a new cephalosporin antibiotic, Cefmenoxime (CMX) Otic Solution for acute purulent otitis media, chronic purulent otitis media, chronic purulent otitis media with sudden exacerbation and acute diffuse otitis externa. Of the 31 patients treated, 24 showed definite improvement.
The main microorganisms detected were Staphylococcus aureus, Pseudomonas aeruginosa and Pseudomonas cepacia, against all of which CMX was effective in terms of MIC tests. It was further observed that CMX has gained better MIC figures and had a broader spectrum than other antibiotic agents such as CP, CEZ, or FRM.
No side effects were observed, and it may be concluded that CMX Otic Solution is clinically useful.
